Sydney M Crago

With a robust pipeline, new hope for Stargardt disease and retinitis pigmentosa may be on the horizon.

In recent panel discussions, leaders in the retina space shared their thoughts around AMD and DME. These key quotes showcase the heart of these discussions.

The podcast by Cognition Therapeutics features a discussion with retinal specialists.

Ocular Therapeutic, Rezolute, and Opthea will all present at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York City in September.

DMEI is 1 of only 17 centers in the US certified to provide this specialized treatment. Previously, patients in the region who qualified for LUXTURNA would have had to travel to other states to receive treatment.

This office supports Akari’s current expansion of operations as the company prepares to start of enrollment in 2 registrational nomacopan Phase 3 clinical trials in pediatric and adult HSCT-TMA and the start of PAS-nomacopan clinical trials in GA.

EyeSouth Partners has partnered with Retina and Vitreous of Texas, a retina-only practice in Houston, Texas. The company’s current network encompasses 38 practices and over 300 doctors who deliver medical and surgical eye care services across more than 180 locations.

The experimental gene therapy was administered as a treatment in part of a randomized, partially masked, controlled, phase 3 clinical study evaluating the efficacy and safety of an experimental therapy, ABBV-RGX-314, for wet AMD.

We asked, "What research at ASRS 2023 do you find exciting or interesting?" Here's what Paul Hahn, MD, Kerrie Brady, BPharm, MBA, MS, and Michael Singer, MD had to say!

Our team spoke with several researchers and industry professionals at the 2023 American Society of Retina Specialists meeting in Seattle, Washington. We asked them, "What research here do you find exciting or interesting?" Here's what Tarek Hassan, MD, Nancy Lurker, and J. Fernando Arevalo, MD, PhD, FACS, FASRS, had to say!

At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Diana Do, MD, Shawn Kavoussi, MD, and Durga Borkar, MD, MMCi had to say!

At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Ursula Schmidt-Erfurth, MD, Veena Raiji, MD, and Dante Pieramici, MD had to say!

"What research at the 2023 ASRS meeting do you find exciting or interesting?" Here's what Aaron Lee, MD, Megan Baldwin PhD, and Carl Danzig, MD had to say!

Sruthi Arepalli, MD, spoke with our team about the current landscape of geographic atrophy (GA) and her presentation at the Women in Ophthalmology Summer Symposium being held in Marco Island, Florida.

The findings of this study shed new light on processes such as learning and memory but also the development of blinding conditions.

Adverum Biotechnologies, Inc. provided an update on the company’s ongoing Phase 2 LUNA trial evaluating ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD).

Kerrie Brady, Chief Executive Officer and President of OcuTerra Therapeutics shared updates from the company including the development of OTT166 at the 2023 ASRS annual meeting.

David Lally, MD, spoke with our team about the ZETA-1 phase 2 trial efficacy results for APX3330, a novel, oral ref-1 inhibitor for the treatment of diabetic retinopathy at the 2023 ASRS annual meeting.

Veena Raiji, MD, MPH, spoke with our team about long-term outcomes of eyes requiring IOP-lowering medication in the PALADIN trial at the 2023 ASRS annual meeting.

J. Fernando Arevalo, MD, PhD, FACS, FASRS, a member of Modern Retina's editorial advisory board, spoke with us about clinical characteristics of macular holes that close without surgery.

At the 2023 ASRS annual meeting in Seattle, Washington, Michael Singer, MD, spoke with our team about the Starlight Study, which is an optogenetic study looking at patients who had Stargardt disease.

Aleksandra Rachiskaya, MD, a member of the Modern Retina advisory board, spoke with our team about time to fluid control with faricimab arms complete compared to aflibercept in recent studies at the 2023 ASRS annual meeting.

Nancy Lurker, Executive Vice-Chair of the Board of EyePoint Pharmaceuticals, discussed the subgroup analyses of the Phase 1 DAVIO Trial of EYP-1901 with our team at the 2023 ASRS annual meeting.

Paul Hahn, MD, PhD, shared insights on research comparing the relative efficacy of pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy presented at the 2023 ASRS annual meeting.

President and CEO at Outlook Therapeutics, Russ Trenary, shared an update on the company's work toward FDA approval for Bevacizumab with our team at the 2023 ASRS annual meeting.

Megan Baldwin, PhD, CEO and Managing Director of Opthea Limited, spoke with our team about the company's clinical trial drug OPT-302 (sozinibercept) at the 2023 ASRS annual meeting.

Tarek Hassan, MD, spoke with our team about a novel glyco-mimetic nanoparticle, Aviceda AVD-104, being developed for the treatment of geographic atrophy.

At the 2023 ASRS annual meeting in Seattle, Washington, Ursula Schmidt-Erfurth, MD, spoke with our team to share information on the GALE extension study.

The Modern Retina team caught up with one of our board members, Fernando Arevalo, MD, PhD, FACS, FASRS, who shared information on his presentation on the treatment of progressively symptomatic retinal detachments associated with retinoschisis cases at the 2023 ASRS annual meeting.

At the 2023 ASRS annual meeting, Dante Pieramici, MD, spoke with our team to share information on OPT-302, or sozinibercept, for the treatment of neovascular AMD and other retinal vascular diseases.